Get the Stockscreener App
24.35
3.94%
-1.00
After Hours:
24.35
Ideaya Biosciences Inc stock is traded at $24.35, with a volume of 877.70K.
It is down -3.94% in the last 24 hours and up +15.84% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$25.35
Open:
$25.08
24h Volume:
877.70K
Relative Volume:
0.74
Market Cap:
$2.13B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.12
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
-1.93%
1M Performance:
+15.84%
6M Performance:
+0.00%
1Y Performance:
-43.44%
1-Day Range:
$24.22
$25.69
1-Week Range:
$24.22
$26.16
52-Week Range:
$13.45
$44.04
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
24.35 | 2.22B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
How does IDEAYA Biosciences Inc. compare to its industry peersChart Pattern Planner For Beginners - jammulinksnews.com
What is IDEAYA Biosciences Inc. company’s growth strategyPost Market Review For 2025 - jammulinksnews.com
Mizuho lowers Ideaya Biosciences stock price target to $43 on pipeline review - Investing.com Canada
Will IDEAYA Biosciences Inc. bounce back from current supportRisk-Managed Swing Setup and Signal Analysis - Newser
Is IDEAYA Biosciences Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Applying Wyckoff theory to IDEAYA Biosciences Inc. stockSwing Setup With Technical Confirmation Explained - metal.it
Chart based analysis of IDEAYA Biosciences Inc. trendsAsset Allocation Summary With Future Outlook - Newser
Will IDEAYA Biosciences Inc. outperform the marketNext Day Momentum Stock Forecasting Report - Newser
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionFree Proven Entry Plan With Low Risk Trade - Newser
Will IDEAYA Biosciences Inc. stock benefit from AI tech trendsWatchlist Generator With Real-Time Entry - Newser
JPMorgan Chase & Co. Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock Price - Defense World
How volatile is IDEAYA Biosciences Inc. stock compared to the marketRetirement Planning Updates For Consistent Profits - jammulinksnews.com
TD Cowen Initiates Coverage of IDEAYA Biosciences (IDYA) with Buy Recommendation - MSN
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - MSN
Historical volatility pattern of IDEAYA Biosciences Inc. visualizedProven Trading System with Consistent Gains - Newser
Can IDEAYA Biosciences Inc. rally from current levelsSwing Entry Insight With Forecast Accuracy - Newser
Analyzing net buyer seller activity in IDEAYA Biosciences Inc.Trade Flow Monitor with Volume Tracker - Newser
Evaluating IDEAYA Biosciences Inc. with trendline analysisDaily Pick Forecast with Entry Zones - Newser
What catalysts could drive IDEAYA Biosciences Inc. stock higher in 2025High-octane gains - jammulinksnews.com
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com
IDEAYA Biosciences Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Investing Community - Newser
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Invest smarter with data-backed trading alerts - jammulinksnews.com
What drives IDEAYA Biosciences Inc. stock priceSignificant capital appreciation - PrintWeekIndia
TD Cowen Bullish on Ideaya’s (IDYA) Oncology Pipeline - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Research Coverage Started at TD Cowen - Defense World
What analysts say about IDEAYA Biosciences Inc. stockTriple-digit profit margins - PrintWeekIndia
Is IDEAYA Biosciences Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia
What makes IDEAYA Biosciences Inc. stock price move sharplyFree Investing Community - Newser
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - The Malaysian Reserve
IDEAYA to present phase 2 data on uveal melanoma drug at ESMO - Investing.com Nigeria
IDEAYA to present phase 2 data on uveal melanoma drug at ESMO By Investing.com - Investing.com South Africa
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy - Nasdaq
IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest
IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan
Signaturefd LLC Increases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - The Malaysian Reserve
IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):